United States - English - NLM (National Library of Medicine)

dispensing solutions, inc. - calcitriol (unii: fxc9231jvh) (calcitriol - unii:fxc9231jvh) - calcitriol 0.25 ug - predialysis patients calcitriol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (ccr 15 to 55 ml/min) not yet on dialysis. in children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. a serum ipth level of ≥ 100 pg/ml is strongly suggestive of secondary hyperparathyroidism. dialysis patients calcitriol is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. in these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. hypoparathyroidism patients calcitriol is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidi

United States - English - NLM (National Library of Medicine)

dispensing solutions, inc. - misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) - misoprostol 200 ug - misoprostol is indicated for reducing the risk of nsaid (nonsteroidal anti-inflammatory drugs, including aspirin)–induced gastric ulcers in patients at high risk of complications from gastric ulcer, e.g., the elderly and patients with concomitant debilitating disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of ulcer. misoprostol has not been shown to reduce the risk of duodenal ulcers in patients taking nsaids. misoprostol should be taken for the duration of nsaid therapy. misoprostol has been shown to reduce the risk of gastric ulcers in controlled studies of 3 months' duration. it had no effect, compared to placebo, on gastrointestinal pain or discomfort associated with nsaid use. see boxed warnings. misoprostol should not be taken by pregnant women to reduce the risk of ulcers induced by nonsteroidal anti-inflammatory drugs (nsaids). misoprostol should not be taken by anyone with a history of allergy to prostaglandins.

United States - English - NLM (National Library of Medicine)

dispensing solutions, inc. - diphenoxylate hydrochloride (unii: w24od7yw48) (diphenoxylate - unii:73312p173g), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - diphenoxylate hydrochloride 2.5 mg - diphenoxylate hydrochloride and atropine sulfate tablets are effective as adjunctive therapy in the management of diarrhea. diphenoxylate hydrochloride and atropine sulfate tablets are contraindicated in patients with - known hypersensitivity to diphenoxylate or atropine, - obstructive jaundice, - diarrhea associated with pseudomembranous enterocolitis or enterotoxin-producing bacteria.

United States - English - NLM (National Library of Medicine)

dispensing solutions, inc. - orphenadrine citrate (unii: x0a40n8i4s) (orphenadrine - unii:al805o9og9) - orphenadrine citrate 100 mg - orphenadrine citrate extended-release tablets are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions. orphenadrine citrate extended-release tablets are contraindicated in patients with glaucoma, pyloric or duodenal obstruction, stenosing peptic ulcers, prostatic hypertrophy or obstruction of the bladder neck, cardio-spasm (mega-esophagus) and myasthenia gravis. orphenadrine citrate tablets are contraindicated in patients who have demonstrated a previous hypersensitivity to the drug. orphenadrine has been chronically abused for its euphoric effects. the mood elevating effects may occur at therapeutic doses of orphenadrine.

United States - English - NLM (National Library of Medicine)

dispensing solutions, inc. - hydrocodone bitartrate (unii: no70w886kk) (hydrocodone - unii:6yks4y3wq7), acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d) - hydrocodone bitartrate and acetaminophen tablets are indicated for the relief of moderate to moderately severe pain. this product should not be administered to patients who have previously exhibited hypersensitivity to hydrocodone or acetaminophen. patients known to be hypersensitive to other opioids may exhibit cross-sensitivity to hydrocodone. hydrocodone bitartrate and acetaminophen tablets contain hydrocodone, an opioid agonist, and is a schedule iii controlled substance. hydrocodone bitartrate and acetaminophen tablets, and other opioids, used in analgesia can be abused and are subject to criminal diversion. addiction is a primary, chronic, neurobiologic disease, with genetic, psychosocial, and environmental factors influencing its development and manifestations. it is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving. drug addiction is a treatable disease utilizing a multidisciplinary approach, bu

United States - English - NLM (National Library of Medicine)

dispensing solutions, inc. - hydrocodone bitartrate (unii: no70w886kk) (hydrocodone - unii:6yks4y3wq7), acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d) - hydrocodone bitartrate and acetaminophen tablets are indicated for the relief of moderate to moderately severe pain. this product should not be administered to patients who have previously exhibited hypersensitivity to hydrocodone or acetaminophen. patients known to be hypersensitive to other opioids may exhibit cross-sensitivity to hydrocodone. hydrocodone bitartrate and acetaminophen tablets contain hydrocodone, an opioid agonist, and is a schedule iii controlled substance. hydrocodone bitartrate and acetaminophen tablets, and other opioids, used in analgesia can be abused and are subject to criminal diversion. addiction is a primary, chronic, neurobiologic disease, with genetic, psychosocial, and environmental factors influencing its development and manifestations. it is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving. drug addiction is a treatable disease utilizing a multidisciplinary approach, bu

United States - English - NLM (National Library of Medicine)

dispensing solutions, inc. - prednisone (unii: vb0r961hzt) (prednisone - unii:vb0r961hzt) - prednisone 2.5 mg - prednisone tablets and solutions are indicated in the following conditions: primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice: synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy), ankylosing spondylitis, acute and subacute bursitis, acute nonspecific tenosynovitis, acute gouty arthritis, post-traumatic osteoarthritis, synovitis of osteoarthritis, epicondylitis. during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus, systemic dermatomyositis (polymyositis), acut

United States - English - NLM (National Library of Medicine)

dispensing solutions, inc. - loperamide hydrochloride (unii: 77ti35393c) (loperamide - unii:6x9oc3h4ii) - loperamide hydrochloride 2 mg - loperamide hydrochloride capsules are indicated for the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease. loperamide hydrochloride capsules are also indicated for reducing the volume of discharge from ileostomies. loperamide hydrochloride capsules are contraindicated in patients with a known hypersensitivity to loperamide hydrochloride or to any of the excipients. loperamide hydrochloride is contraindicated in patients with abdominal pain in the absence of diarrhea. loperamide hydrochloride is not recommended in infants below 24 months of age. loperamide hydrochloride should not be used as the primary therapy: - in patients with acute dysentery, which is characterized by blood in stools and high fever, - in patients with acute ulcerative colitis, - in patients with bacterial enterocolitis caused by invasive organisms including salmonella, shigella, and campylobacter, - in patients with pseudomembranous colitis associated with the u

United States - English - NLM (National Library of Medicine)

dispensing solutions, inc. - raltegravir potassium (unii: 43y000u234) (raltegravir - unii:22vkv8053u) - raltegravir 400 mg - isentress® is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv-1) infection. this indication is based on analyses of plasma hiv-1 rna levels in three double-blind controlled studies of isentress. two of these studies were conducted in clinically advanced, 3-class antiretroviral (nnrti, nrti, pi) treatment-experienced adults through 96 weeks and one was conducted in treatment-naïve adults through 156 weeks. the use of other active agents with isentress is associated with a greater likelihood of treatment response [see clinical studies (14)] . isentress is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in children and adolescents 2 years of age and older and weighing at least 10 kg [see use in specific populations (8.4)] . this indication is based on the evaluation of safety, tolerability, pharmacokinetic parameters and efficacy of isentress through at least 24-weeks in a multi-center, open-label, non

United States - English - NLM (National Library of Medicine)

dispensing solutions, inc. - ergocalciferol (unii: vs041h42xc) (ergocalciferol - unii:vs041h42xc) - ergocalciferol 1.25 mg - ergocalciferol capsules, usp are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin d resistant rickets, and familial hypophosphatemia. ergocalciferol capsules, usp are contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin d, and hypervitaminosis d.